Avacta Group Plc (AVCT.L)
| Previous close | 45.30 |
| Open | 45.01 |
| Bid | 44.50 x 0 |
| Ask | 45.00 x 0 |
| Day's range | 44.00 - 45.50 |
| 52-week range | 43.00 - 166.98 |
| Volume | |
| Avg. volume | 3,165,805 |
| Market cap | 161.569M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
5 April 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) AVA6000 Abstract Release by AACR and Full Presentation Update Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the American Association of Cancer Research (“AACR”) Annual Meeting in San Diego, California on Tuesday 9 April has now been released by AACR. The poster presentation will
- Globe Newswire
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide dru
- Globe Newswire
Appointment of Chief Business Officer
19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals commercial emphasis for Avacta to leverage clinical progress Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division. Simon has over 26 years’ commercial experience in the biopharm
